Bortezomib subcutaneous versus intravenous: analysis of the incidence of bortezomib-induced peripheral neuropathy in Korean patients with multiple myeloma

Trial Profile

Bortezomib subcutaneous versus intravenous: analysis of the incidence of bortezomib-induced peripheral neuropathy in Korean patients with multiple myeloma

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2015

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2015 New trial record
    • 06 Aug 2014 Results published in the journal of Cancer Chemotherapy and Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top